Arca
Skip to content
Tools
Tools

Label Changes: Pifeltro (doravirine)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Pifeltro label DailyMed has published, from Merck Sharp & Dohme LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 13
  • Sections changed, version 20 to 21: 8

What changed from version 20 to version 21

Nov 18, 2025 to Jul 13, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Warnings and precautionsChanged ยท 42 words added, 6 removed
  2. Adverse reactionsChanged ยท 10 words added
  3. Clinical pharmacologyChanged ยท punctuation or symbols only
  4. Clinical studiesChanged ยท punctuation or symbols only
  5. Patient counseling informationChanged ยท 22 words added, 4 removed
  6. Patient informationChanged ยท 151 words added, 140 removed
  7. Untitled sectionChanged ยท 2 words added, 2 removed
  8. Untitled sectionChanged ยท 4 words added, 4 removed

Warnings and precautions

Changed42 words added, 6 removed
5 WARNINGS AND PRECAUTIONS
5.1 Severe Skin Reactions
5.1 Skin and Hypersensitivity Reactions
Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens [see Adverse Reactions (6.2)]. In addition, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome) was reported in a clinical trial with a two-drug regimen containing doravirine. Discontinue PIFELTRO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or, a progressive severe rash, or a rash with constitutional symptoms, eosinophilia, lymphadenopathy, or other organ involvement develops. Clinical status should be closely monitored, and appropriate therapy should be initiated.
5.2 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions
5 unchanged lines

Adverse reactions

Changed10 words added
1 unchanged line
The following adverse reactions are discussed in other sections of the labeling:
Skin and Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
Immune Reconstitution Syndrome [see Warnings and Precautions (5.3)]
112 unchanged lines

Clinical pharmacology

Changedpunctuation or symbols only
82 unchanged lines
Clinical Trial Results in Adults with No Antiretroviral Treatment History
In the doravirine treatment arms of the DRIVE-FORWARD and DRIVE-AHEAD trials (n=747) through Week 96, 13 participants showed the emergence of doravirine resistance-associated substitutions in their HIV among 36 (36%) participants in the resistance analysis subset (participants with HIV-1 RNA greater than 400 copies per mL at virologic failure or early study discontinuation and having post-baseline resistance samples). Emergent doravirine resistance-associated substitutions in RT included one or more of the following: V90G/I, A98G, V106A, V106I, V106M/T, V108I, E138G, Y188L, H221Y, P225H, P225L, P225P/S, F227C, F227C/R, Y318Y/F and Y318Y/S. Eight of 13 (62%) participants with emergent doravirine resistance-associated substitutions showed doravirine phenotypic resistance and most of them had at least a 100-fold reduction in doravirine susceptibility (range: >95- to >211โ€“fold reduction in doravirine susceptibility). The other 5 virologic failures who had only amino acid mixtures of NNRTI resistance substitutions showed doravirine phenotypic fold-changes of less than 2-fold. Of the 36 participants in the resistance analysis subset, 10 participants (28%) developed genotypic and/or phenotypic resistance to the other drugs (abacavir, emtricitabine, lamivudine, or tenofovir) in the regimens of the DRIVE-FORWARD and DRIVE-AHEAD trials. The resistance-associated substitutions that emerged were RT M41L (n=1), A62A/V (n=1), K65R (n=2), T69T/A (n=1), V75V/I (n=1), and M184I or V (n=7).
In the DRV/r treatment arm of the DRIVE-FORWARD trial (n=383) through Week 96, no participants showed the emergence of darunavir resistance-associated substitutions among 15 participants with resistance data and 2 of the participants had emergent genotypic or phenotypic resistance to lamivudine or tenofovir. In the EFV/FTC/TDF treatment arm of the DRIVE-AHEAD trial (n=364) through Week 96, 15 participants showed the emergence of efavirenz resistance-associated substitutions among 25 (60%) participants in the resistance analysis subset and genotypic resistance to emtricitabine or tenofovir developed in 5 evaluable participants; emergent resistance-associated substitutions were RT K65R (n=1), D67G/K70E (n=1), L74V/V75M/V118I (n=1), M184I or V (n=5), and K219K/E (n=1).
6 unchanged lines

Clinical studies

Changedpunctuation or symbols only
75 unchanged lines
The efficacy of DELSTRIGO (DOR/3TC/TDF) was evaluated in cohort 2 of an open-label, single-arm 2-cohort trial in pediatric participants 12 to less than 18 years of age living with HIV (IMPAACT 2014 (Protocol 027), NCT03332095). In cohort 1, virologically-suppressed participants (n=9) received a single 100 mg dose of PIFELTRO followed by intensive PK sampling. In cohort 2, virologically-suppressed participants (n=43) were switched to DELSTRIGO and treatment-naรฏve participants (n=2) were started on DELSTRIGO.
In cohort 2, at baseline the median age of participants was 15 years (range: 12 to 17), the median weight was 52 kg (range: 45 to 80), 58% were female, 78% were Asian and 22% were Black, and the median CD4+ T-cell count was 713 cells per mm3 (range: 84 to 1397). After switching to DELSTRIGO, 95% (41/43) of virologically-suppressed participants remained suppressed (HIV-1 RNA <50 copies/mL) at Week 24. One of the two treatment-naรฏve participants achieved HIV-1 RNA <50 copies/mL at Week 24. The other treatment-naรฏve participant met the protocol-defined virologic failure criteria (defined as 2 consecutive plasma HIV-1 RNA test results โ‰ฅ200 copies/mL at or after Week 24) and was evaluated for the development of resistance; no emergence of genotypic or phenotypic resistance to doravirine, lamivudine, or tenofovir was detected.

Patient counseling information

Changed22 words added, 4 removed
1 unchanged line
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Severe Skin Reactions
Skin and Hypersensitivity Reactions
Inform patients that severe skin reactions including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported with PIFELTROdoravirine-containing regimens. Advise patients to immediately contact their healthcare provider if they develop a rash. Instruct patients to immediately stop taking PIFELTRO and seek medical attention if a painful rash with mucosal involvement or a rash with constitutional symptoms develops [see Warnings and Precautions (5.1)].
Drug Interactions
10 unchanged lines

Patient information

Changed151 words added, 140 removed
7 unchanged lines
Take PIFELTRO every day exactly as your healthcare provider tells you to take it. Take PIFELTRO 1 time each day, at about the same time every day. If you take the medicine rifabutin during treatment with PIFELTRO, take PIFELTRO 2 times each day, about 12 hours apart, as prescribed by your healthcare provider. You may not have enough doravirine in your blood if you take rifabutin during treatment with PIFELTRO. Take PIFELTRO with or without food. Do not change your dose or stop taking PIFELTRO without talking to your healthcare provider. Stay under a healthcare provider's care when taking PIFELTRO. It is important that you do not miss or skip doses of PIFELTRO. If you miss a dose of PIFELTRO, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at your regular time. Do not take 2 doses of PIFELTRO at the same time. If you have any questions, call your healthcare provider or pharmacist. When your PIFELTRO supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to PIFELTRO and become harder to treat. What are the possible side effects of PIFELTRO?
PIFELTRO can cause serious side effects, including: Severe skin reactions have happened in people treated with PIFELTRO. Call your healthcare provider right away if you develop a rash during treatment with PIFELTRO. Stop taking PIFELTRO and get medical help right away if you develop a painful rash with any of the following symptoms: fever, blisters or sores in the mouth, blisters or peeling of the skin, or redness or swelling of the eyes (conjunctivitis). Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine. The most common side effects of PIFELTRO include:
PIFELTRO can cause serious side effects, including: Severe skin reactions have happened in people treated with PIFELTRO. Call your healthcare provider right away if you develop a rash during treatment with PIFELTRO. Stop taking PIFELTRO and get medical help right away if you develop a painful rash with any of the following symptoms:
| fever blisters or peeling of the skin feeling tired or generally ill | blisters or sores in the mouth swelling of the face or lymph nodes redness or swelling of the eyes (conjunctivitis)
Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine. The most common side effects of PIFELTRO include:
nausea dizziness headache tiredness | diarrhea stomach (abdominal) pain abnormal dreams
4 unchanged lines

Untitled section

Changed2 words added, 2 removed
2 unchanged lines
The trademarks depicted herein are owned by their respective companies.
Copyright ยฉ 2018-20252026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
uspi-mk1439-t-2510r0082607r009

Untitled section

Changed4 words added, 4 removed
2 unchanged lines
The trademarks depicted herein are owned by their respective companies.
Copyright ยฉ 2018-20242026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
usppi-mk1439-t-2411r0052607r006
For more information, go to www.PIFELTRO.com or call 1-877-888-4231.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 1107/20242026

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Drug interactions, Use in specific populations, Description, Nonclinical toxicology, How supplied, PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label.

Every version

13 versions of set 76ce1f00-28c0-4314-bd2c-d473fe3d0970, newest first.
VersionPublished on DailyMedCompareSPL file
21Jul 13, 2026Shown belowDownload .zip
20Nov 18, 2025With version 18Download .zip
18Nov 22, 2024With version 17Download .zip
17Nov 1, 2024With version 15Download .zip
15Dec 14, 2023With version 14Download .zip
14Nov 9, 2022With version 13Download .zip
13Jun 29, 2022With version 12Download .zip
12Feb 10, 2022With version 11Download .zip
11Oct 25, 2021With version 9Download .zip
9Oct 13, 2020With version 8Download .zip
8Oct 24, 2019With version 7Download .zip
7Sep 27, 2019With version 4Download .zip
4Sep 7, 2018First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.